Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

NCT02943668 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Terminated due to low accrual

Conditions

Anemia
Myelodysplastic Syndrome

Interventions

DRUG: Deferasirox
OTHER: Laboratory Biomarker Analysis

Sponsor

Fred Hutchinson Cancer Center

Collaborators

[object Object]
[object Object]